US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Migraine · Narcolepsy
H. Lundbeck A/S
H. Lundbeck A/S drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
- Employees
- 112
- Programs
- 17
- Drugs
- 14
- Patents
- 0
H. Lundbeck A/S pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
H. Lundbeck A/S drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
eptinezumab
Nervous system (N02)Nervous system (N02) compound in H. Lundbeck A/S's portfolio. Molecular target: Calcitonin gene-related peptide.
- Target
- Calcitonin gene-related peptide
- Mechanism
- Calcitonin gene-related peptide inhibitor
-
US regulatory status: approved. Molecular target: Calcitonin gene-related peptide.
- Target
- Calcitonin gene-related peptide
- Mechanism
- Calcitonin gene-related peptide inhibitor
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.
-
Development asset linked to H. Lundbeck A/S in public FDA and regional records.